

# The Shareholders' Perspective



*Dear Reader,*

Innovation is at the heart of Boehringer Ingelheim. In 2023 our investments in Research & Development (R&D) in Human Pharma grew to 25.1% of net sales, which ranks us among the top R&D investors in the industry. We are committed to upholding these high investment levels to ensure that we bring innovation to patients as fast as possible, knowing that every day that we gain can make a real difference in their lives.

Our independence allows us to research in areas where a long-term commitment is needed to find solutions for unmet needs. Our work in mental health is a good example, aimed at finding treatments for people affected by mental health disorders, such as schizophrenia. We are hopeful that our determination yields successful results, with the first three investigational compounds now progressing into late-stage development.

Our efforts focus on high unmet medical needs, to transform the lives of patients. The innovativeness of our products also shortens hospitalization days, allows for better home care, helps people to return more quickly to active community life, or drives cost down through earlier screening and improved diagnosis. It is our mission to not only help patients with novel treatments, but in doing so also help make healthcare systems more efficient.

At Boehringer Ingelheim we have entered 2024 with great confidence, as we are geared towards 25 new treatment launches in Human Pharma until 2030 and many more in Animal Health. This is only possible thanks to the dedication and passion of our employees. On behalf of the Shareholders' Committee, I would like to express our gratitude to all employees for their commitment.

signed by  
Christian Boehringer  
Chairman of the Shareholders' Committee